<?xml version="1.0" encoding="UTF-8"?>
<ref id="B67-pharmaceuticals-13-00096">
 <label>67.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Emery</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>McInnes</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Genovese</surname>
    <given-names>M.C.</given-names>
   </name>
   <name>
    <surname>Smolen</surname>
    <given-names>J.S.</given-names>
   </name>
   <name>
    <surname>Kremer</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Dougados</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Schlichting</surname>
    <given-names>D.E.</given-names>
   </name>
   <name>
    <surname>Rooney</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Issa</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>De Bono</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies</article-title>
  <source>Ann. Rheum. Dis.</source>
  <year>2016</year>
  <volume>75</volume>
  <fpage>A62</fpage>
  <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209124.147</pub-id>
 </element-citation>
</ref>
